PPARA and metabolic dysfunction-associated steatotic liver disease: The dual PPARα/δ agonist (GFT-505) has shown favorable results in improving atherogenic dyslipidemia and insulin resistance and appears to be a potential candidate for the treatment of non-alcoholic fatty liver disease (NAFLD).